European and Italian regulation on orphan medicinal products

Roberta Joppi

DOI: https://doi.org/10.7175/fe.v14i2.633

Abstract

The paper presents an overview of the European and Italian Regulation on Orphan Medicinal Products (OMPs), along with some data on the OMPs licensed in the EU from 2000 to 2012. The EU legislation encourages pharmaceutical companies to develop drugs for rare diseases, so-called “orphan drugs”. The European Medicine Agency recognizes orphan drug status mainly on the basis of the prevalence of the disease (≤ 5/10,000), and potential benefit. Orphan status implies incentives for pharmaceutical companies. From 2000 up to 2012 890 candidate orphan drug designations received a positive opinion and the marketing authorization was granted to 72 OMPs corresponding to 80 different indications. Currently, 59 OMPs are available to Italian patients either because licensed to the market by the AIFA or included in the list of the L. 648/96. Despite of an encouraging regulation nearly all the currently estimated rare diseases still await treatments.

Keywords

Orphan drugs; Rare diseases; Pharmaceutical legislation

Full Text

HTML PDF

References

  • Orphanet. The portal for rare diseases and orphan drugs. Disponibile su: http://www.orpha.net/consor/cgi-bin/index.php?lng0EN&lng=IT (ultimo accesso: marzo 2013)
  • Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Communities 2000; L18: 1-5
  • EMA. Rare disease (orphan) designations. Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b (ultimo accesso:marzo 2013)
  • Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal 2011; L 311: 67. Disponibile su:http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF (ultimo accesso: marzo 2013)
  • Decreto Ministero della Sanità - 18 maggio 2001, n. 279. Regolamento di istituzione della rete nazionale delle malattie rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie ai sensi dell’articolo 5, comma 1, lettera b) del decreto legislativo 29 aprile 1998, n. 124. G.U. 12 luglio 2001, n. 160
  • ISS. Registro Nazionale Malattie Rare. Disponibile su: http://www.iss.it/cnmr/regi/cont.php?id=860〈=1&tipo=14
  • Taruscio D. Il Registro Nazionale e i Registri Regionali/interregionali delle malattie rare. Rapporto anno 2011. ISS 2011; Rapporti ISTISAN 11/20. Disponibile su: http://www.iss.it/binary/cnmr/cont/ISTISAN_RNMR_2011.pdf
  • Legge 23/12/96 n. 648 di conversione del decreto-legge 21/10/96 n. 536 (G.U. n. 300 del 23 dicembre 1996)
  • Elenco farmaci erogabili a totale carico del SSN ai sensi della legge 648/96 e relative indicazioni terapeutiche. Disponibile su http://www.agenziafarmaco.gov.it (ultimo accesso: marzo 2013)
  • ISS. Registro Nazionale Farmaci Orfani. Disponibile su: http://www.iss.it/orfa/regi/cont.php?id=71〈=1&tipo=4. (ultimo accesso: marzo 2013)
  • EMA. Thelin (sitaxentan) – Withdrawal of the marketing authorisation in the European Union. EMA/149536/2011. Disponibile su: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/03/WC500102595.pdf
  • Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013; 69: 1009-24; http://dx.doi.org/10.1007/s00228-012-1423-2
  • Osservatorio Nazionale sull’impiego dei medicinali. L’Uso dei Farmaci in Italia. Rapporto nazionale anno 2011.

Statistics

Abstract: 2359 views
HTML: 1262 views
PDF: 639 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.